Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Other financing activities (2020 - 2024)

SkinHealth Systems has reported Other financing activities over the past 4 years, most recently at -$302000.0 for Q4 2024.

  • Quarterly Other financing activities rose 15.17% to -$302000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$884000.0 through Dec 2024, down 51.89% year-over-year, with the annual reading at -$302000.0 for FY2024, N/A changed from the prior year.
  • Other financing activities was -$302000.0 for Q4 2024 at SkinHealth Systems, up from -$356000.0 in the prior quarter.
  • Over five years, Other financing activities peaked at $21.3 million in Q3 2021 and troughed at -$21.3 million in Q4 2021.
  • The 4-year median for Other financing activities is -$226000.0 (2023), against an average of -$26388.3.
  • The largest YoY upside for Other financing activities was 9044.59% in 2021 against a maximum downside of 4680.51% in 2021.
  • A 4-year view of Other financing activities shows it stood at $465909.0 in 2020, then crashed by 4680.51% to -$21.3 million in 2021, then soared by 98.33% to -$356000.0 in 2023, then increased by 15.17% to -$302000.0 in 2024.
  • Per Business Quant, the three most recent readings for SKIN's Other financing activities are -$302000.0 (Q4 2024), -$356000.0 (Q4 2023), and -$226000.0 (Q3 2023).